Literature DB >> 6430691

Interactions between anticonvulsants and other commonly prescribed drugs.

H Kutt.   

Abstract

Many drug interactions can be demonstrated, but only a few are so clinically significant that they necessitate adjusting drug dosages. The same drug combination may produce changes of variable extent or direction in different individuals. The reasons for this variability include genetic control of the rate and inducibility of drug metabolism, and environmental factors such as contact with chemicals. Among antimicrobial agents, chloramphenicol may cause accumulation of phenytoin (PHT) and phenobarbital (PB), and isoniazid may cause PHT, carbamazepine (CBZ), and primidone (PRM) to accumulate. Erythromycin may cause accumulation of CBZ. Among anti-ulcer agents, antacids may reduce PHT concentration while cimetidine may cause accumulation of PHT, CBZ, and diazepam (DZP). Salicylates displace strongly binding drugs such as PHT, DZP, or valproate (VPA) from the binding sites in plasma proteins, which may lead to some decline of the total plasma level with an increase in the unbound drug percentage. Conversely, anticonvulsants may influence the dosage requirements of oral anticoagulants by inducing their metabolism. Failures of oral contraceptives have been attributed to anticonvulsants in some patients. Probably the most predictable interaction that necessitates dosage adjustment is accumulation of PB caused by VPA. Intentional inhibition of PRM metabolism by nicotinamide serves as an example of attempts to utilize an interaction for improved therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430691     DOI: 10.1111/j.1528-1157.1984.tb05644.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  16 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 3.  Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.

Authors:  N Principi; S Esposito
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

Review 4.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients. Preliminary pharmacokinetic results.

Authors:  A J Loonen; P J Toll; J R Nijdam
Journal:  Pharm Weekbl Sci       Date:  1989-02-24

6.  Effect of febrile illness and its treatment on anticonvulsant levels in children.

Authors:  K J Goulden
Journal:  CMAJ       Date:  1986-06-15       Impact factor: 8.262

Review 7.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Managing epilepsy in women of childbearing age.

Authors:  Pamela M Crawford
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.